PharmAust (PAA) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PAA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Neurizon Therapeutics Reports Significant Loss Amidst Strategic ShiftFebruary 16, 2025 | tipranks.com‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantelMay 20, 2024 | msn.comPharmAust inks approval from Macquarie University for Open-Label MND extension studyApril 10, 2024 | msn.comWe Think PharmAust (ASX:PAA) Can Afford To Drive Business GrowthMarch 27, 2024 | finance.yahoo.comClosing Bell: ASX a little lower after hosting a Big 4 bank midweek spankMarch 14, 2024 | msn.comPharmAust files groundbreaking MND/ALS clinical data with the FDAMarch 14, 2024 | msn.comIf you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 nowMarch 13, 2024 | fool.com.auPharmAust advances monepantel for motor neurone disease towards FDA approvalFebruary 28, 2024 | finance.yahoo.comPharmAust Limited: PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSFebruary 28, 2024 | finanznachrichten.dePharmAust’s MPL could offer MND/ALS sufferers up to 56.5 months additional life expectancyFebruary 28, 2024 | msn.comPharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSFebruary 28, 2024 | finance.yahoo.comPharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALSFebruary 21, 2024 | msn.comFDA shows the way for accelerated approval of PharmAust’s monepantel in MNDFebruary 16, 2024 | msn.comPharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week aloneFebruary 14, 2024 | finance.yahoo.comPharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’February 13, 2024 | msn.comPlains All American Pipeline LP PAAFebruary 10, 2024 | morningstar.comMPlains All American Pipeline L.P.January 31, 2024 | markets.businessinsider.comPlains All American Stock (NASDAQ:PAA) Dividends: History, Yield and DatesJanuary 30, 2024 | benzinga.comPharmAust gets ethics committee green light for open-label MND extension studyJanuary 30, 2024 | msn.comFDA offers PharmAust clear guidance for orphan drug designation approvalJanuary 28, 2024 | msn.comPlains All American Pipeline LPJanuary 23, 2024 | morningstar.comMPharmAust partners with US-based Berry Consultants for Phase 2/3 studyJanuary 16, 2024 | msn.comPharmAust just got a pre-IND meeting with the US FDA to kick off ‘24January 1, 2024 | msn.comUp to $1.8m funding from motor neurone disease foundation could be on the table for PharmAustDecember 21, 2023 | msn.comSanta (and ATO) delivers PharmAust $550k cash boost for ChristmasDecember 20, 2023 | msn.comProminent Perth fundie the main backer in PharmAust’s $3.5m cap raiseDecember 12, 2023 | msn.comPharmAust Limited (ECQ.F)December 2, 2023 | au.finance.yahoo.comPharmAust completes Phase 1 motor neurone disease trial, applies for Orphan Drug DesignationNovember 30, 2023 | msn.comWhy this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases marketNovember 21, 2023 | msn.comPharmAust Ltd PAANovember 9, 2023 | morningstar.comMPharmAust eyes US orphan drug designation after successful phase 1 motor neurone disease trialOctober 12, 2023 | msn.comPharmAust races for access to the US market after confirming its canine cancer treatment is safe for poochesOctober 8, 2023 | msn.comPharmAust Full Year 2023 Earnings: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)September 2, 2023 | finance.yahoo.comNew CEO to take the helm as PharmAust progresses clinical studiesAugust 28, 2023 | msn.comResults from 11 out of 12 patients in PharmAust trial point to stabilised MND progressionAugust 22, 2023 | msn.comPreliminary evidence for MPL activity enables PharmAust to commence planning a Phase 2 trial in motor neurone diseaseAugust 8, 2023 | msn.comPAA.AX - PharmAust LimitedJuly 12, 2023 | finance.yahoo.comPharmAust secures more proof of MPL’s efficacy in stopping MND progressionJuly 11, 2023 | msn.comPharmAust begins Cohort 3 dosing in Phase 1/2 motor neurone disease trialJune 9, 2023 | msn.comPharmAust confirms safety of MPL, poised to up dosage in MND trialMay 22, 2023 | msn.comPharmAust’s interim analysis to point the way forward for MND trialMay 15, 2023 | msn.comPharmAust says its MPL drug has a long and stable shelf lifeMay 9, 2023 | msn.comPharmAust’s MPL drug shows anti-cancer effects across multiple cancer typesMay 8, 2023 | msn.comPharmAust’s oversubscribed $2.5m placement highlights investor backingMay 3, 2023 | msn.comPharmAust secures more MPL tablets to safeguard supply for motor neurone disease trialApril 17, 2023 | msn.comPharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease marketMarch 29, 2023 | msn.comHere's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn SituationMarch 28, 2023 | finance.yahoo.comPharmAust’s MND trial progressing with ‘stable’ patient moving to higher dosageMarch 27, 2023 | msn.comPharmAust Limited (PAA.AX)March 15, 2023 | uk.finance.yahoo.comLouie the beagle is beating the odds thanks to PharmAust’s canine cancer trialMarch 8, 2023 | msn.com Get PharmAust News Delivered to You Automatically Sign up to receive the latest news and ratings for PAA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PAA Media Mentions By Week PAA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PAA News Sentiment▼0.000.71▲Average Medical News Sentiment PAA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PAA Articles This Week▼00▲PAA Articles Average Week Get the Latest News and Ratings for PAA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for PharmAust and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SB News ESEA News PAC News CLCO News BLDE News ASC News PANL News FLYX News RLGT News SHIP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PAA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmAust Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmAust With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PAA Stock Alerts